Literature DB >> 19223511

The complex relationship between BRCA1 and ERalpha in hereditary breast cancer.

Julia J Gorski1, Richard D Kennedy, Alison M Hosey, D Paul Harkin.   

Abstract

Breast cancer 1 (BRCA1) was initially identified as one of the genes conferring genetic predisposition to both breast and ovarian cancer. One of the interesting aspects of BRCA1-linked cancers is the observed specificity for estrogen-responsive tissues such as breast and ovary. Recent advances in our understanding of BRCA1-linked breast cancers have revealed a complex relationship between BRCA1 and estrogen receptor alpha (ERalpha) signaling. Estrogen stimulation increases expression of BRCA1 at the mRNA and protein level and conversely BRCA1 functions to both induce ERalpha mRNA expression and act as a negative regulator of ERalpha signaling. Here, we review the relationship between BRCA1 and ERalpha and discuss the use of antiestrogen therapies such as tamoxifen and aromatase inhibitors in the treatment of BRCA1 mutation carriers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19223511      PMCID: PMC2780737          DOI: 10.1158/1078-0432.CCR-08-0640

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  45 in total

1.  Role of direct interaction in BRCA1 inhibition of estrogen receptor activity.

Authors:  S Fan; Y X Ma; C Wang; R Q Yuan; Q Meng; J A Wang; M Erdos; I D Goldberg; P Webb; P J Kushner; R G Pestell; E M Rosen
Journal:  Oncogene       Date:  2001-01-04       Impact factor: 9.867

2.  Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.

Authors:  H Ruffner; C A Joazeiro; D Hemmati; T Hunter; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

3.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.

Authors:  M Esteller; J M Silva; G Dominguez; F Bonilla; X Matias-Guiu; E Lerma; E Bussaglia; J Prat; I C Harkes; E A Repasky; E Gabrielson; M Schutte; S B Baylin; J G Herman
Journal:  J Natl Cancer Inst       Date:  2000-04-05       Impact factor: 13.506

4.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

5.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

Authors:  Sunil R Lakhani; Marc J Van De Vijver; Jocelyne Jacquemier; Thomas J Anderson; Peter P Osin; Lesley McGuffog; Douglas F Easton
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

6.  p300 Modulates the BRCA1 inhibition of estrogen receptor activity.

Authors:  Saijun Fan; Yong Xian Ma; Chenguang Wang; Ren-Qi Yuan; Qinghui Meng; Ji-An Wang; Michael Erdos; Itzhak D Goldberg; Paul Webb; Peter J Kushner; Richard G Pestell; Eliot M Rosen
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

7.  BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor.

Authors:  L Zheng; L A Annab; C A Afshari; W H Lee; T G Boyer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

8.  Cancer Incidence in BRCA1 mutation carriers.

Authors:  Deborah Thompson; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

9.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

Authors:  Marcia S Brose; Timothy R Rebbeck; Kathleen A Calzone; Jill E Stopfer; Katherine L Nathanson; Barbara L Weber
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

Review 10.  The relationship between factors affecting endogenous oestradiol levels in postmenopausal women and breast cancer.

Authors:  Elizabeth J Folkerd; Lesley-Ann Martin; Anne Kendall; Mitch Dowsett
Journal:  J Steroid Biochem Mol Biol       Date:  2006-10-17       Impact factor: 4.292

View more
  25 in total

1.  Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese.

Authors:  Da Pang; Yashuang Zhao; Weinan Xue; Ming Shan; Yanbo Chen; Youxue Zhang; Guoqiang Zhang; Feng Liu; Dalin Li; Yanmei Yang
Journal:  Med Oncol       Date:  2011-11-11       Impact factor: 3.064

2.  Responsiveness of Brca1 and Trp53 Deficiency-Induced Mammary Preneoplasia to Selective Estrogen Modulators versus an Aromatase Inhibitor in Mus musculus.

Authors:  Sahar J Alothman; Weisheng Wang; David S Goerlitz; Md Islam; Xiaogang Zhong; Archana Kishore; Redha I Azhar; Bhaskar V Kallakury; Priscilla A Furth
Journal:  Cancer Prev Res (Phila)       Date:  2017-03-10

3.  Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.

Authors:  Ming-Fen Ho; Tim Bongartz; Mohan Liu; Krishna R Kalari; Paul E Goss; Lois E Shepherd; Matthew P Goetz; Michiaki Kubo; James N Ingle; Liewei Wang; Richard M Weinshilboum
Journal:  Mol Endocrinol       Date:  2016-02-11

Review 4.  Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.

Authors:  Priscilla A Furth; M Carla Cabrera; Edgar S Díaz-Cruz; Sarah Millman; Rebecca E Nakles
Journal:  Ann N Y Acad Sci       Date:  2011-07       Impact factor: 5.691

5.  Transcriptional regulation of BRCA1 expression by a metabolic switch.

Authors:  Li-Jun Di; Alfonso G Fernandez; Adriana De Siervi; Dan L Longo; Kevin Gardner
Journal:  Nat Struct Mol Biol       Date:  2010-11-21       Impact factor: 15.369

6.  Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers.

Authors:  Nadine Tung; Alexander Miron; Stuart J Schnitt; Shiva Gautam; Katharina Fetten; Jennifer Kaplan; Yosuf Yassin; Ayodele Buraimoh; Ji-Young Kim; Attila M Szász; Ruiyang Tian; Zhigang C Wang; Laura C Collins; Jane Brock; Karen Krag; Robert D Legare; Dennis Sgroi; Paula D Ryan; Daniel P Silver; Judy E Garber; Andrea L Richardson
Journal:  Breast Cancer Res       Date:  2010-11-16       Impact factor: 6.466

7.  BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression.

Authors:  M Yan; M Rayoo; E A Takano; H Thorne; S B Fox
Journal:  Br J Cancer       Date:  2009-09-01       Impact factor: 7.640

8.  A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.

Authors:  Rachael Natrajan; Alan Mackay; Maryou B Lambros; Britta Weigelt; Paul M Wilkerson; Elodie Manie; Anita Grigoriadis; Roger A'Hern; Petra van der Groep; Iwanka Kozarewa; Tatiana Popova; Odette Mariani; Samra Turaljic; Simon J Furney; Richard Marais; Daniel-Nava Rodruigues; Adriana C Flora; Patty Wai; Vidya Pawar; Simon McDade; Jason Carroll; Dominique Stoppa-Lyonnet; Andrew R Green; Ian O Ellis; Charles Swanton; Paul van Diest; Olivier Delattre; Christopher J Lord; William D Foulkes; Anne Vincent-Salomon; Alan Ashworth; Marc Henri Stern; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2012-02-23       Impact factor: 7.996

9.  Prenatal polycyclic aromatic hydrocarbons, altered ERα pathway-related methylation and expression, and mammary epithelial cell proliferation in offspring and grandoffspring adult mice.

Authors:  Debashish Sahay; Susan E Lloyd; Janelle A Rivera; Jacqueline Jezioro; Jacob D McDonald; Masha Pitiranggon; Beizhan Yan; Matthias Szabolcs; Mary Beth Terry; Rachel L Miller
Journal:  Environ Res       Date:  2021-03-04       Impact factor: 6.498

10.  Examining the pathogenesis of breast cancer using a novel agent-based model of mammary ductal epithelium dynamics.

Authors:  Joaquin Chapa; Ryan J Bourgo; Geoffrey L Greene; Swati Kulkarni; Gary An
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.